TS-003666 — This advancement in pharmacology targets iron-sulfur cluster biogenesis in mammalian cells. Through the utilization of N’-(1-phenylethylidene)-benzohydrazides, originally developed as LSD1 inhibitors, this discovery highlights their additional inhibitory activity against iron-sulfur cluster biogenesis in mitochondrial environments. With a potent inhibitory effect demonstrated (100s of nM IC50), it holds potential implications as an anticancer, antimicrobial, and/or antiviral agent, independent of any inhibitory action against LSD1. The project is positioned at the proof-of-concept stage, and future work aims to delineate the relationship between iron-sulfur cluster disruption and LSD1 biology, further investigate mitochondrial disruption further, and identify specific targets for potential therapeutic intervention. The disclosed IP is a unique approach to targeting iron-sulfur cluster biogenesis and presents opportunities for diverse commercial applications in the pharmaceutical industry.

TS-003665 — This is a new avenue in genetic research focused on iron-sulfur cluster pathway disruptors. These disruptors, including N’-(1-(2-hydroxyphenyl)-propylidene)-benzohydrazides and N’-(1-(2-hydroxyphenyl)-ethylidene)-benzohydrazides, offer potential applications in altering the iron-sulfur cluster maturation process. Their development signifies a departure from previously explored compounds, particularly those with LSD1 inhibitory activity, thus introducing cleaner compounds for targeted disruption. Ongoing proof of concept testing is slated for completion by year-end. The IP offers a promising path for therapeutic exploration, and the potential applications of these disruptors span various human pathologies, including cancer and infectious diseases.